Knowledge Base

AimwellBio is a biopharmaceutical intelligence operating system designed to deliver verified, actionable insights to decision-makers in life sciences. We combine proprietary data collection, AI-powered analysis, and multi-layer verification to surface what matters most—with confidence scores that let you know exactly what's been verified, inferred, or flagged for human review.

The Cortex AI Engine is our proprietary intelligence processor that ingests structured and unstructured data from hundreds of sources, applies machine learning models trained on biopharmaceutical domain expertise, and subjects every claim to multi-layer verification before delivery. It generates briefings, flags anomalies, and enforces hallucination containment across six independent verification layers.

After registration, complete your profile with your organization and role. Then configure your notification preferences, set your time zone, and designate any team members who should have access to shared briefings. Your initial briefing will be generated within 24 hours based on your company focus.

Define your focus areas by adding therapeutic areas, target companies, competitor companies, regulatory bodies, or key decision-makers. You can create multiple watchlists for different teams or initiatives. Each watchlist generates its own briefing stream and alert rules, allowing granular control over what intelligence reaches whom.

Your first briefing appears in your dashboard and email as a curated summary of verified intelligence relevant to your focus areas. It includes executive summaries, key developments, risk signals, and compliance alerts. Each item carries a confidence score (Confirmed, Inferred, Monitoring, or Blocked) explaining the verification status.

Navigate to the "Dossiers" section and select "Request New Dossier." Specify your subject (company, individual, or topic), choose your tier (Signal, Shield, or Command), and submit. Our intelligence team will compile comprehensive research with verified source citations and deliver your dossier within your tier's SLA (typically 24–72 hours).

Daily briefings contain curated intelligence organized into sections: Executive Summary, Confirmed Developments, Emerging Signals, Compliance & Regulatory, Competitive Landscape, and Risk Alerts. Each section surfaces only the highest-relevance items for your watchlists, filtered by confidence and recency. Briefings are delivered via email and dashboard every morning.

Confirmed: Verified across multiple independent sources or primary documents. Inferred: Derived from reliable secondary sources but not yet independently confirmed. Monitoring: Potential signal flagged for further investigation—not yet verified. Blocked: Claim failed verification checks and is held from delivery. Confidence scores help you assess risk and decide what requires human follow-up.

Each briefing item includes a source citation linking to the original document or announcement. Evidence IDs are unique identifiers for the intelligence claim, allowing you to track its history and audit trail. Click any evidence ID to view the complete verification record, including all sources consulted and verification timestamps.

Verified: The claim has passed our six-layer verification pipeline and exists in at least two independent sources. Unverified: The claim comes from a single source or has not yet completed verification. Unverified items appear in the "Monitoring" section and are flagged for follow-up—they may become verified as additional evidence arrives.

Our Cortex Engine runs each claim through multiple independent AI models trained on different aspects of biopharma intelligence (regulatory, clinical, commercial, technical). Each model scores the claim's credibility. Only claims that pass threshold scoring across models advance to the next verification layer. This multi-model consensus prevents single-model bias and hallucination.

Choose your briefing cadence: Daily (every morning), Weekly (each Monday), or Custom (specify your preferred days/times). You can set different schedules for different watchlists. Real-time alert notifications are always available regardless of briefing schedule. Premium tiers unlock intraday briefings for breaking developments in your priority areas.

Hallucination occurs when an AI model generates plausible-sounding but false or unsupported claims. In intelligence work, this is catastrophic: a fabricated clinical trial result, a fake FDA approval, or a false executive departure can drive bad decisions. AimwellBio's architecture treats hallucination prevention as the primary design constraint, not an afterthought.

Layer 1: Source discipline—all claims trace back to verifiable sources. Layer 2: Multi-model consensus—claims validated across independent AI models. Layer 3: Human review for novel claims—material developments flagged for analyst verification. Layer 4: Cross-source triangulation—claims must exist in at least two independent sources. Layer 5: Temporal consistency—claims checked for logical timeline alignment. Layer 6: Domain expert override—our team can veto AI-generated claims that violate domain knowledge.

Cortex generates candidate intelligence claims from source data. These move to the Verify stage where they're checked against our knowledge base and source registry. If verification succeeds, the claim moves to Finalize. If it fails, the claim is Revised (rephrased or downgraded in confidence) and re-verified. Only Finalized claims reach your briefing.

We maintain six specialized AI models: Regulatory Affairs, Clinical Intelligence, Commercial Insights, Executive Movement, Technical Assessment, and Compliance. When a claim is generated, all six models independently evaluate it. The claim only advances if at least four models exceed our confidence threshold. This consensus approach eliminates model-specific blind spots.

When a claim fails verification (contradicts sources, lacks evidence, or triggers multiple red flags), it's marked "Blocked" and never reaches your briefing. Instead, it's logged in the Hallucination Containment Dashboard for audit purposes. You can review blocked claims to understand what our system rejected and why—full transparency into our false-positive controls.

Navigate to Admin → Hallucination Containment to view a log of all claims that were generated but blocked. Filter by date, subject, or reason (e.g., "source contradiction," "insufficient evidence"). Each blocked claim shows which verification layers rejected it and why. This dashboard is crucial for auditing system behavior and building trust in your intelligence feed.

From your dashboard, navigate to Watchlists and create a new list or edit an existing one. Add entities by name (companies, executives, regulatory bodies, drugs, therapeutic areas). Use wildcards and filters to create broad patterns (e.g., "all clinical-stage oncology companies") or narrow specificity (e.g., "Amgen's cardiac division"). Save and your briefings will update within minutes.

Critical: FDA action, executive departure, M&A announcement, or major clinical failure—delivered instantly. High: Confirmed developments in your focus areas—delivered within 1 hour. Medium: Emerging signals or inferred developments—delivered in next briefing. Low: Monitoring items or tangential developments—delivered in weekly digest. Customize severity thresholds per watchlist.

From Account Settings, configure notification channels (email, SMS, Slack integration, push to mobile app). Set delivery windows (e.g., "no alerts before 7am or after 6pm"). Create rules per watchlist (e.g., "only Critical severity to SMS, everything else to email"). You can also subscribe to briefing-only mode to silence all alerts and receive briefings on schedule.

AimwellBio tracks normal patterns for each watchlist entity (typical press release frequency, news volume, leadership changes). When activity deviates significantly from the baseline—e.g., a quiet company suddenly generates 10 news items in one day—our system flags an anomaly alert. This catches unusual developments before headlines confirm them.

Escalation: A developing story gaining confirmation, spreading to new sources, or intensifying impact (e.g., a clinical hold initially reported by one outlet now covered by major press). De-escalation: Previous story losing momentum, being retracted, or contradicted. Our system tracks signal momentum and alerts you to both when situations are heating up and when they're cooling down.

Signal: Quick 10-page overview on any subject, delivered within 24 hours. Good for initial research. Shield: Comprehensive 30-50 page deep-dive with verified sources, regulatory history, and risk assessment. Delivered within 48 hours. Command: Executive-grade 100+ page strategic dossier with scenario analysis, source appendix, and ongoing monitoring. Delivered within 72 hours with quarterly updates.

From your dashboard, click "Request Dossier." Specify your subject (company, individual, drug, therapeutic area), select your tier, and add any specific questions or focus areas. Submit and receive immediate confirmation. Our team begins research immediately; you'll receive updates as the dossier develops and delivery notification when it's ready.

Dossiers follow a consistent structure: Executive Summary, Company/Subject Overview, Strategic Position, Competitive Landscape, Regulatory & Compliance Status, Financial Performance (where applicable), Risk Factors, Leadership & Key Personnel, and Outlook. Each section is self-contained so you can jump to areas most relevant to your decision.

Every dossier includes a detailed Evidence Appendix listing all sources consulted (press releases, SEC filings, clinical trial registries, regulatory databases, patent records, news archives). Source Lineage shows how each claim traces back to original sources. Click any reference to view the full source document. This transparency allows your team to conduct independent verification.

All dossiers are available as branded PDF downloads. PDFs include full formatting, source citations, and a table of contents for easy navigation. Download your dossier from the dashboard or from your email notification. Command-tier dossiers come with an executive summary one-pager that can be extracted for presentation purposes.

FHIN (Federal Health Intelligence Network) is AimwellBio's crowdsourced intelligence collaborative. Industry professionals submit vetted data, insights, and observations in exchange for credits and access to enhanced briefings. FHIN amplifies the quality of our intelligence by incorporating diverse perspectives from across the biopharma ecosystem.

Navigate to FHIN in the main menu and select "Become a Contributor." Complete the contributor profile (name, area of expertise, organization affiliation if applicable). Submit sample contributions for review. Once approved, you'll gain access to the contributor portal where you can submit observations, clinical insights, competitive intelligence, and regulatory intelligence for community review and credit rewards.

Each FHIN submission is scored on accuracy, relevance, timeliness, and source documentation. Contributions verified against external sources receive higher quality scores. Contributors build reputation over time as their submissions are validated. High-quality contributors receive priority review and higher credit rewards. The system is designed to incentivize accurate, well-sourced intelligence.

Contributors earn credits for each accepted submission based on quality score and impact. Credits can be redeemed for subscription discounts, premium dossier tiers, or additional watchlist slots. Top contributors receive monthly bonuses and exclusive access to early research on trending topics. Credits never expire and can be pooled across team members.

Submissions can be attributed to your profile or submitted anonymously. Attributed contributions build your reputation and earn higher visibility. Anonymous contributions are valuable for sensitive competitive insights or situations where attribution could present conflicts of interest. You choose the publication method for each submission based on your comfort level.

FHIN submissions feed directly into our training data and verification systems. High-quality contributions improve our AI models' domain understanding and reduce false positives. Verified FHIN insights become sources for future briefings, creating a virtuous cycle: contributors see their intelligence reflected in the briefings of thousands of subscribers, creating real impact from their expertise.

All data in transit uses TLS 1.3 encryption. At rest, briefings and dossiers are encrypted with AES-256. Our infrastructure is hosted on AWS with compliance certifications across SOC2, ISO27001, and FedRAMP. Encryption keys are managed separately from data and rotated quarterly. Backups are geographically distributed and tested monthly for recovery integrity.

AimwellBio maintains HIPAA Business Associate Agreement (BAA) coverage for customers handling protected health information (PHI). Our platform includes HIPAA-compliant audit trails, access controls, and de-identification protocols for clinical data. If your organization handles PHI, ensure your account has BAA coverage activated in Admin Settings before processing any health data.

All accounts require multi-factor authentication (MFA). We support SMS, authenticator apps, and FIDO2 hardware keys. Single sign-on (SSO) is available for enterprise customers via SAML or OAuth. Role-based access controls (RBAC) let admins assign permissions per user: read-only, briefing editor, watchlist manager, admin. Inactive accounts are automatically disabled after 90 days.

Every action—login, briefing view, dossier download, watchlist edit, form submission—is logged with timestamp, user, IP, and action details. Audit logs are retained for 7 years and are immutable (cannot be deleted or modified). Admins can export audit logs from Admin → Compliance for regulatory review. Critical actions trigger real-time security alerts.

Briefings are retained indefinitely in your account. You can request deletion of specific items from Admin → Data Deletion. Dossiers are retained for 5 years unless you request deletion. Account deletion removes all personal data within 30 days; aggregate analytics are retained anonymously for 7 years. We never sell personal data or briefing content to third parties.

Signal: Daily briefing, 3 watchlists, 1 dossier/month. Shield: Premium briefing, 10 watchlists, 3 dossiers/month, premium dossier tier. Command: Executive briefing, unlimited watchlists, 10 dossiers/month, command tier dossiers, FHIN contributor status. Enterprise: Custom briefing, white-label option, custom integrations, dedicated support, compliance certifications (HIPAA, SOC2, FedRAMP).

From Account → Billing, select your desired plan and click "Change Plan." Changes take effect immediately. Upgrades are prorated to your next billing date. Downgrades take effect on your next renewal date (no mid-cycle refunds). If downgrading removes features you're using (e.g., dossier slots), you'll receive a 30-day notice with the opportunity to export or archive items before access is removed.

Update your payment method, billing address, and invoice email from Account → Billing → Payment Methods. Download invoices and receipt PDFs anytime from Billing History. Set up automatic renewals or manage billing contacts. We accept all major credit cards and offer annual prepay discounts (15% off). Invoices are issued on the renewal date and sent automatically to your billing email.

Organizations with 50+ team members, specialized compliance needs, or custom integration requirements qualify for enterprise pricing. Contact our sales team at sales@aimwellbio.com to discuss volume discounts, custom SLAs, and white-label options. Enterprise customers receive dedicated account managers and custom onboarding support.